Regenerative Medicine Industry Showcased at Upcoming World Stem Cell Summit in Detroit, Oct. 4-6

Organizers Say Summit Will Lead to Funding, Products and Collaborations

WASHINGTON--(BUSINESS WIRE)-- Tom Okarma, President and CEO of Geron Corporation and keynote speaker at the 2010 World Stem Cell Summit taking place at the Detroit Marriott Renaissance Center from Oct. 4-6, describes the Summit as “the one meeting that we at Geron feel is a must attend, and we are pleased to tell our story to its audience.”

That view is echoed by the Alliance for Regenerative Medicine (ARM), a Washington-based lobbying group that includes in its membership many leading companies. ARM is hosting its general membership meeting at the Summit. Included will be representatives from Johnson & Johnson, Athersys, Beckman Coulter, Corning, iPerian and dozens of other companies and venture firms engaged in the burgeoning field.

“We are very pleased that the Industry Track of the Summit Program presents the best and the brightest,” said Bernard Siegel, founder and co-chair of the World Stem Cell Summit and executive director of the Genetics Policy Institute (GPI). “Our industry panels are designed to address the needs of the life science investor community and executives from biotechnology, pharmaceutical and other regenerative medicine companies.”

Some of the expert industry panels include:

  • The Outlook for the Cord Blood, Cell Therapy and Bio Banking Industries
  • Devices and Tools for Research and Industry
  • Financing Pathways for Cell Based Therapies
  • Michigan's Role in Stem Cell Research and as a Center for Regenerative Medicine Commercialization
  • Stem Cell Standardization Issues
  • Pathways to Commercializing Stem Cell Therapies - Tech Transfer Perspectives
  • Reimbursement and Insurance Solutions for Cell Therapies and Related Industries
  • Regenerative Medicine Under the Microscope—VC and Investor Perspectives
  • Pharma's Growing Investment in Regenerative Medicine
  • The Shifting Landscape of Intellectual Property Law and Its Impact on the Future of Regenerative Medicine
  • Forging Relationships between Industry and Regulators
  • Commercialization of Stem Cells and International Market Trends
  • Hospital Perspectives on Stem Cells and Regenerative Medicine
  • Partnering and M&A: Inside Information from the Regen Dealmakers
  • Global Clinical Trials Update
  • Regenerative Medicine Against Aging—Technological, Political and Commercial Obstacles and Opportunities
  • Economic Development—Stem Cells and Regenerative Medicine as an Engine for Economic Growth
  • Finding Common Ground—The Emerging Alliance Between Advocates and Industry
  • Healing Our Wounded Warriors—Armed Forces Investment in Regenerative Medicine

The co-hosts for the 2010 Summit include the State of Michigan, the Michigan Economic Development Corporation, and the University Research Corridor, members of which are the University of Michigan, Michigan State University and Wayne State University.

In 2010, the Summit will attract more than 1,000 attendees from 30 nations, 60 exhibitors and more than 200 endorsing organizations and media partners. Science & Education partners include Oakland University and The Taubman Foundation. Some of the diverse sponsors and endorsers include the American Red Cross, the Harvard Stem Cell Institute, the Foundation Fighting Blindness, and, among public companies, Beckman Coulter, Millipore, NeoStem and Roche.

The largest and most comprehensive multi-track stem cell conference, the Summit features more than 150 international speakers and 50 hours of in-depth science, business and society presentations. No other stem cell conference offers the breadth of content and global perspective. The agenda works to unite, educate and harmonize the global stem cell community. For more information and to register, visit www.worldstemcellsummit.com.



CONTACT:

The Genetics Policy Institute
Bernard Siegel, 305-801-4928
[email protected]

KEYWORDS:   United States  North America  District of Columbia  Michigan

INDUSTRY KEYWORDS:   Stem Cells  Health  Biotechnology  Genetics  Public Policy/Government  Pharmaceutical  Other Policy Issues  Public Policy  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.